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Abstract: One of the ultimate goals of wound healing research is to find effective healing 
techniques that utilize the regeneration of similar tissues. This involves the modification of 
various wound dressing biomaterials for proper wound management. The biopolymer 
chitosan (-1,4-D-glucosamine) has natural biocompatibility and biodegradability that 
render it suitable for wound management. By definition, a biocompatible biomaterial does 
not have toxic or injurious effects on biological systems. Chemical and physical 
modifications of chitosan influence its biocompatibility and biodegradability to an 
uncertain degree. Hence, the modified biomedical-grade of chitosan derivatives should be 
pre-examined in vitro in order to produce high-quality, biocompatible dressings. In vitro 
toxicity examinations are more favorable than those performed in vivo, as the results are 
more reproducible and predictive. In this paper, basic in vitro tools were used to evaluate 
cellular and molecular responses with regard to the biocompatibility of biomedical-grade 
chitosan. Three paramount experimental parameters of biocompatibility in vitro namely 
cytocompatibility, genotoxicity and skin pro-inflammatory cytokine expression, were 
generally reviewed for biomedical-grade chitosan as wound dressing. 
 
Keywords: Biopolymer, chitosan, biocompatibility, biomedical-grade chitosan, in vitro 
toxicity examinations, cytocompatibility, genotoxicity, skin pro-inflammatory cytokine 
expression. 
 
OPEN ACCESSInt. J. Mol. Sci. 2009, 10                 
 
1301
Contents 
 
1. Introduction 
2. Chitosan derivatives in wound management 
3. Biocompatibility in vitro of biomedical-grade chitosan derivatives 
4. Biocompatibility in vitro experimental tools 
4.1. Cytocompatibility assessment in vitro 
4.2. Genotoxicity assessment in vitro 
4.3. Assessment of human skin pro-inflammatory cytokines  
5.  Future considerations and conclusion       
Acknowledgments 
References 
 
     
1. Introduction 
 
This paper generally reviews the literature on the in vitro models for biocompatibility assessment of 
chitosan derivatives for use in human wound management. Wound healing is a process of restoration 
that is necessary for tissue repair, typically comprising a continuous sequence of inflammation and 
repair in which epithelial, endothelial, inflammatory cells, platelets and fibroblasts briefly interact to 
resume their normal functions. This healing process consists of four different and overlapping phases, 
namely: inflammation, granulation tissue formation, matrix remodeling and reepithelialization [1]. The 
orderly sequence of healing events is performed and regulated by cytokines and growth factors [2]. 
One of the ultimate goals in wound healing research involves finding ways for humans to heal via the 
regeneration of similar tissues. This could be accomplished via the invention and modification of a 
variety of dressing materials to facilitate proper wound management.  
Chitosan is a partially deacetylated derivative of natural chitin, a primary structural polymer in 
arthropod exoskeletons. One of the present trends in biomedical research requires materials that are 
derived from nature as natural materials have been shown to exhibit better biocompatibility with 
humans. For example, chitosan’s monomeric unit, N-acetylglucosamine, occurs in hyaluronic acid, an 
extracellular macromolecule that is important in wound repair. It has been considered as a candidate 
natural polymer for the scaffold since chitosan shows several advantages over other synthetic 
biomaterials and easy manipulation of stable porous structure by lyophilization. Studies on chitosan 
have been intensified since 1990 due to its low cytotoxicity, antimicrobial activity and excellent 
biodegradable properties in the human body, where these have contributed to the better 
biocompatibility of chitosan [3-6]. Additionally, the N-acetylglucosamine moiety in chitosan is 
structurally similar to glycosaminoglycans (GAGs), heparin, chondroitin sulphate and hyaluronic acid 
in which they are biocompatible, and hold the specific interactions with various growth factors, 
receptors and adhesion proteins besides being the biologically important mucopolysaccharides and in 
all mammals. Therefore, the analogous structure in chitosan may also exert similar bioactivity and 
biocompatibility [7-8].  Int. J. Mol. Sci. 2009, 10                 
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The potential of chitosan stems from its cationic nature and high charge density in solution. An 
effective approach for developing a clinically applicable chitosan is to modify the surface of the 
material that already has excellent biofunctionality and bulk properties. Widely used surface 
modification techniques include coating, oxidation by low-temperature plasma and surfactant addition 
in order to blend with various derivatives. However, blending technologies with various additives may 
cause cytotoxicity. Hence, the modified biomedical-grade of chitosan with various derivatives should 
be submitted for biocompatibility testing to promote the engineering of high-quality, biocompatibility 
for human wound management. 
 
2. Chitosan Derivatives in Wound Management 
 
Chitosan (-1,4-D-glucosamine) is a deacetylated form of chitin with excellent biological properties 
in wound management [9-11]. Altering the physical and chemical properties of the chitosan in order to 
improve its medicinal quality will also influence its biocompatibility. Chitosan oligosaccharides with a 
degree of polymerization (DP) between 6 and 8 were found to have antitumor activity [12]. The high 
percentage of nitrogen (6.89%) found in chitosan has made it a useful chelating agent [13]. Their 
unique properties include polyoxysalt formation, as well as the ability to form films and chelate metal 
ions [14].  
The excellent biological properties of chitosan can be potentially improved with a variety of 
additional chemicals such as polyethylene glycol and carboxymethyl, N-acyl groups in order to 
produce biocompatible chitosan derivatives for use as wound dressings [15]. Chitosan’s positive 
surface charge enables it to effectively support cell growth [16]. Chitosan-gelatin sponge wound 
dressing had demonstrated a superior antibacterial effect, as mediated by vacuum driness on 
Escherichia coli K88, in comparison to that of penicillin. Furthermore, chitosan gelatin-sponge wound 
dressing displayed a superior healing effect to that of 0.2% (v/v) ethacridine. Additionally, chitosan-
gelatin sponge allowed the wound site to contract markedly and shortened the wound healing time, as 
compared with sterile Vaseline gauze [17]. Clinical assessment was performed using a Hyphecan cap 
(1-4,2-acetamido-deoxy-β-D-glucan), as a biological fingertip dressing and was proven to be effective 
in achieving a good functional and cosmetic result within a relatively short time, aside from being 
comfortable during conventional dressing changes [9].  
 
3. Biocompatibility In Vitro of Biomedical-Grade Chitosan Derivatives 
 
Biocompatibility of a biomaterial refers to the extent to which the material does not have toxic or 
injurious effects on biological systems. In the pre-commercialization steps of a biomedical-grade 
chitosan derivative as wound dressing, it is of great importance that the dressing be submitted to a 
number of pre-toxicity tests, in vitro or in vivo. Chitosan is a cationic polymer having an amino group 
in its chemical structure. Anti-tumor, anti-microbial and anti-inflammatory can be largely attributed to 
the cationic structure. Lee et al. [18] performed trypan blue dye exclusion cytotoxicity assays on tumor 
cell lines, after increased positive charge density of chitosan by dialkylaminoalkylation and reductive 
amination followed by quaternization. Cytotoxicity of chitosan with various degrees of N-
deacetylation to form aminoethyl-chitosan, dimetylaminoethyl-chitosan and diethylaminoethyl-Int. J. Mol. Sci. 2009, 10                 
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chitosan, was examined only with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide 
(MTT) on tumor cell lines and concluded that cytotoxic effect may be caused by cationic charge of the 
chitosan derivatives [19]. Amino groups of chitosan attached with biologically active moieties such as 
vanillin,  p-hydroxybenzaldehyde,  p-chlorobenzaldehyde, anisaldehyde, methyl 4-hydroxybenzoate, 
methyl 2,4-dihydroxybenzoate, propyl 3,4,5-trihydroxybenzoate and 2-hydroxymethylbenzoate can 
promote anti-microbial ability [20].  
A thorough understanding of cell and proteins interactions with artificial surfaces is of importance 
to design suitable implant surfaces and substrates. The surface properties of newly synthesized 
biomedical-grade chitosan derivatives, including surface composition, wettability, domain composition, 
surface oxidation, surface charge and morphology, may influence protein adsorption and subsequently, 
the cellular responses to biomaterial implants. Though it has once been suggested that surfaces 
modified with polyethylene glycol (PEG) may limit protein adsorption and cell adhesion, the results 
for PEG blended with chitosan increased both the adsorption and the cell adhesion [21]. Zhang et al. 
[22] examined the biocompatibility of newly synthesized chitosan-PEG by growing and observing the 
morphological changes of 3T3 embryonic mouse fibroblasts and osteogenesis nodule cell suspension 
in culture. Cytotoxicity of chitosan in three dimensional fiber meshes was well determined with only 
scanning electron microscopy (SEM) and cell morphological observation on the use of mouse lung 
fibroblast (L929) [23]. Recent studies have been focused on the development of antibacterial surfaces 
of biomedical-grade chitosan derivatives to attain high functionality and high-value products. Huh et al. 
[24] prepared chitosan-grafted poly(ethylene terepthalate) (PET) and quaternized chitosan-grafted PET, 
both showed high growth inhibition in the range of 75% to 86% and still retained 48% to 58% 
bacterial growth inhibition after laundering. But, higher antibacterial activity of a wound dressing can 
retard the cell growth in culture. Laminin is known to be involved in metastasis of tumor cells. A 
peptide containing the Tyr-Ile-Gly-Ser-Arg (YIGSR) sequence, corresponding to a partial sequence of 
laminin, inhibited angiogenesis and therefore depressed tumor growth. Nishiyama et al. [25] prepared 
YIGSR-chitosan conjugate and proved to have higher inhibitory activity against experimental lung 
metastasis of B16BL6 melanoma cells in mice than did the parent peptide. According to Koo et al. 
[26], water-soluble chitosan (WSC) significantly protected from serum starvation-induced cellular 
rounding up and from serum starvation-induced cell death as tested by flow-cytometry. WSC also 
protected from serum starvation-induced p53 activation as determined by the Western blot technique. 
From these results, it appears that WSC may prevent serum starvation-induced apoptosis of human 
astrocytes via p53 inactivation. Cross-linking will increase the toxicity of chitosan scaffold leachate to 
fibroblast cells. However, the chitosan crosslinked with dimethyl 3-3,dithio-bis-propionimidate (DTBP) 
permitted cell proliferation after three days in culture [27]. Denuziere et al. [28] examined the 
cytocompatibility of films of chitosan and chitosan associated with glycosaminoglycans (GAGs) with 
human skin keratinocytes and found that the cell growth was consistent approximately 60% of that of 
controls. Highly deacetylated chitosans can modulate human skin cell mitogenesis in vitro. Analysis of 
their effects on cells in culture may be useful as a screen for their potential activity in vivo as wound 
healing agents. But, it is important to select appropriate strains of cells for use in the in vitro 
biocompatibility screening [29]. Still, most of the biocompatibility in vitro screenings to date for 
chitosan derivatives confined at cellular responses and reactions, namely at the cytocompatibility   
level [30-34].  Int. J. Mol. Sci. 2009, 10                 
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4. Biocompatibility In Vitro Experimental Tools 
 
In vitro models for testing the biocompatibility of biodegradable chitosan and their derivatives are 
very useful to characterize the hidden toxic effects of leachable materials or derivatives, such as 
residual monomers, catalysts as well as other polymer erosion related properties, such as chemical 
compositions, molecular weight, polydispersity, degradation rate and so forth. Cytotoxicity assays 
measure only finite effects on cells during the first 12 to 24 hours after exposure to toxic substances. 
The host cells either recover from or succumb to their chemical injury. However, many biological 
reactions in vivo are not simply cytotoxic and are propagated beyond 24 hours. Examples are improper 
cells programmed apoptosis and necrosis due to DNA damage; inflammatory and immune reactions 
that all resulted from non-biocompatible chitosan derivatives. 
In vitro toxicity examinations are preferable to in vivo tests since the newly developed dressing 
materials can be examined outside the body and the results are more reproducible, facilitating clinical 
evaluation of a medicinal product that can be replicated and estimated [35-36]. It is necessary to 
determine the biocompatibility of any biomaterial in order to evaluate its strength, esthetics and 
feasibility for clinical manipulation. Thus, preliminary in vitro tests are continually being carried out to 
screen and characterize the potentially harmful effects of a dressing material before it is commercially 
used on humans [15]. However, in vitro tests may not fully capture the in vivo situation; differences in 
sensitivities have been observed between primary and established cell lines [37-38]. Current 
regulations in accordance with the United States Food and Drug Administration (FDA), the 
International Organization for Standardization (ISO) and the Japanese Ministry of Health and Welfare 
(JMHW) require that manufacturers conduct adequate safety testing of their finished devices through 
pre-clinical and clinical trials as part of the regulatory clearance process. Toxicity induced by a 
chemical substance or drug can limit the dose and duration of treatment, adversely affect patients’ 
quality of life or even be life threatening. Side effects together with tissue toxicity will lead to long-
term effects such as alteration to the immune system and development of malignancies, probably due 
to the genetic damage induced by a certain kind of drug treatment [39]. Hence, biocompatibility 
assessment in vitro is necessary to evaluate cellular and molecular responses to the newly developed 
biomedical-grade chitosan derivatives. 
 
4.1. Cytocompatibility assessment in vitro 
 
There are a number of assays which are capable of evaluating the activation of biological processes 
(e.g. inflammation, immune reactions and mutagenesis), which require longer periods of tissue 
reaction to materials, as compared with cytotoxic reactions. Traditional assays have measured 
cytotoxicity using either an end-stage event (e.g. permeability of cytoplasmic membranes of dead and 
dying cells, or some metabolic parameters such as cell division or  enzymatic reaction) [40]. 
Cytotoxicity assays are commonly used to measure the effects on cells during exposure to toxic 
substances at multiple concentrations and time course parameters.  The colorimetric 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay is a simple assay which is used 
to identify detrimental intracellular effects on mitochondria and metabolic activity, based on the 
selective ability of viable cells to reduce tetrazolium bromide into purple formazan crystals, which are Int. J. Mol. Sci. 2009, 10                 
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only soluble in organic solvents. The extent of formazan crystal formation depends on intact metabolic 
activity and is frequently used for cytotoxicity screening [41]. The MTT assessment to the 
cytocompatibility was adequately good and the results were easily interpreted, besides being cost 
effective [32-36].  
In our previous research paper [42], in vitro biocompatibility evaluation of biomedical-grade oligo-
chitosan (O-C) and N,O-carboxymethyl-chitosan (NO-CMC) derivatives (O-C 1%, O-C 5%, NO-CMC 
1% and NO-CMC 5%) correlated well with in vivo results in which O-C 1% being the most 
cytocompatible. The experiment was carried out as described by the International Standards 
Organization (ISO) [43], with some modifications. One of the most basic and important parameters in 
the  in vitro measurement of a medicinal product’s biocompatibility is cytocompatibility, which 
measures the qualitative and quantitative aspects of the impact of a medicinal product with regard to 
the viability of target cultured cells. Biomedical-grade chitosan derivatives are to be used primarily in 
human wound management. Thus, the target cultured cells in our research are primary normal human 
skin epidermal keratinocytes (pNHEK) and primary normal human skin dermal fibroblasts (pNHDF), 
which are primarily found in the skin epidermis and dermis respectively. Several transformed 
keratinocyte culture models have been used to study carcinogenesis, differentiation, apoptosis and cell 
cycle regulation [44]. Our focus here is on normal (non-transformed) keratinocyte culture models 
because cutaneous toxicity testing of new drugs, cosmetic products and other chemicals requires 
phenotypically normal cell systems [45]. This is because the loss of differentiated function in 
transformed cell types undoubtedly confounds interpretation of the results [46]. Some have suggested 
that a better correlation of in vitro toxicity testing with irritation potential in vivo may be obtained by 
using normal keratinocyte culture models as opposed to transformed cell lines [47]. Furthermore, 
various in vitro systems are used for cutaneous toxicity testing, ranging from submerged keratinocyte 
and liquid-air interface skin cultures to three-dimensional reconstructed skin models. However, our 
focus here is on submerged monolayer epidermal keratinocyte culture models. The primary reason for 
this focus is a key concept in support of incorporating keratinocyte culture models into a battery of 
cutaneous toxicity tests, namely keratinocytes make up the bulk (greater than 90%) of epidermal tissue 
mass [48], and viable keratinocytes (not exposed directly to air) participate in the conversion of 
environmental stimuli into biological signals that activate the inflammatory and hyper-proliferative 
responses of the skin [49]. Therefore, submerged cultures of epidermal keratinocytes model a major 
component of the target epidermal tissue, allowing an assessment of the effects of drugs or chemicals 
on the skin. The use of low-density polyethylene (LDPE) as negative control is also recommended in 
the ISO cytotoxicity guidelines. LDPE is widely used in the manufacture of petri dishes and culture 
flasks, where LDPE is proven to be non-toxic to cultured cells. The comparison between control 
without any treatment and negative control (with LDPE) indicated in all tests that the cells in the 
negative control condition were slightly lesser than the untreated cells. This effect might be due to the 
weight impact of LDPE on cultured cells. LDPE might slightly inhibit the circulation of the enriched 
medium from the upper level to the lower level of a culture well. The net cytotoxicity effect of the 
biomedical-grade chitosan on cultured cells can be evaluated more accurately if they are compared to 
the negative control in order to eliminate the impact on physical weight from the calculation.  
 
 Int. J. Mol. Sci. 2009, 10                 
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4.2. Genotoxicity assessment in vitro 
 
Although the measures of a medical product's biocompatibility have largely been reported in terms 
of irritation, sensitization, and systemic toxicity, there is a growing concern that devices or biomaterial 
extracts may exert some genotoxic effects, even though they may be cytocompatible in 
cytocompatibility in vitro assessment. Thus, any attempts to assess the safety of a device intended for 
intimate body contact or permanent implantation would be incomplete without testing for the presence 
of toxins that might exert an effect on the genetic material of cells. Genotoxic effects will eventually 
lead to abnormal and reduced cell growth, even if the cells initially appear cytocompatible. In its set of 
standards for the biological evaluation of medical devices, the ISO has outlined the need for such 
genotoxicity testing in ISO 10993-3 [50]. A number of techniques for detecting deoxyribonucleic acid 
(DNA) damage as opposed to the biological results (e.g. Ames test, micronuclei, mutations, structural 
chromosomal aberrations) [51-54] of DNA damage have been used long time ago to identify 
substances with genotoxic activity. According to Muramatsu et al. [55], they did not detect any 
genotoxicity performed via Ames test and chromosome aberration assay, on Chinese hamster lung 
fibroblasts with 5mg/mL (maximum concentration) of beta-tricalcium phosphate/carboxymethyl-
chitin. Abou Sereih et al. [56] reported that their chitosan with concentrations 3.00 and 4.50 mg/mL 
have induced mutation on Trichoderma. However, those techniques have some shortcomings (e.g. time 
investment, requirement for proliferating cell populations) [57-60].  
Until recently, a more useful approach for assessing DNA damage has been the single-cell gel 
electrophoresis (SCGE) or Comet assay. The term “Comet” is used to denote the individual cell DNA 
migration patterns produced. Ostling and Johanson were the first to develop a microgel electrophoresis 
technique for detecting DNA damage at the single-cell level [61]. For this technique, cells were 
embedded in agarose and placed on a microscope slide. The cells were lysed by detergents and high 
salt concentration to liberate the DNA. The liberated DNA was then electrophoresed under neutral 
conditions. Therefore, cells with an increased frequency of DNA double strand breaks (DSB) 
displayed increased migration of DNA toward the anode. The migrating DNA was then assessed 
quantitatively by staining with ethidium bromide using a microscope photometer. The neutral 
conditions used greatly limited the general utility of the assay for detecting the DSB of a cell. 
Subsequently, the microgel technique was introduced, which involved the use of electrophoresis under 
alkaline (pH >13) conditions for detecting DNA single strand breaks (SSB) and alkali-labile sites 
(ALS) in a single cell [62]. Consequently, alkaline electrophoresis offers enhanced sensitivity for 
identifying various unexpected genotoxic agents that tend to induce more SSB and ALS than DSB. 
The Comet assay requires only a few cells per assay, and it is also cost effective [63]. Many excellent 
reviews on the use of the Comet assay used aquatic animals to assess DNA damage caused by 
genotoxicants [64-66]. In addition, production of DNA strand breaks correlates well with the 
mutagenic and carcinogenic properties of environmental pollutants [65]. Therefore, application of 
comet assay to evaluate the genotoxicity of various newly modified chitosan derivatives can be   
another approach. 
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4.3. Assessment of human skin pro-inflammatory cytokines 
 
There are limited studies on the use of skin pro-inflammatory cytokines to assess the 
biocompatibility of various chitosan derivatives to date. Cytokines are low molecular weight 
glycoproteins produced by immune as well as non-immune cells. Their roles in regulating 
immunologic responses, hematopoietic development, and cell-to-cell communication, as well as host 
responses to infectious agents and inflammatory stimuli, have been widely investigated. Cytokines 
mediate interactions between various cells and their dysregulated production may lead to disease 
pathogenesis [67]. Under normal circumstances, cytokines are not detectable at low levels in body 
fluids or in tissues. Therefore, their elevated levels of expression could indicate activation of cytokine 
pathways associated with inflammation or disease progression. All cytokines are pleiotropic: they are 
able to interact with a variety of cellular targets via specific receptors expressed on the surface of target 
cells. The binding of cytokines to cell surface receptors will initiate RNA signaling and protein 
synthesis [68]. Cytokines function as networks or cascades of interacting cytokines, where they are 
able to induce the expression of other cytokines by regulating their own production through autocrine, 
juxtacrine or paracrine pathways in response to micro-environmental stimuli. Keratinocytes are able to 
secrete a number of inflammatory cytokines [e.g. interleukin 1 (IL-1), tumor necrosis factor- 
(TNF-)] and chemotactic cytokines [e.g. interleukin-8 (IL-8)] when they come in contact with 
irritants [69]. The changes in cytokine levels could potentially be used as biomarkers of cutaneous 
vesicant injury [70]. Research on toxicity and inflammation in normal human epidermal keratinocyte 
(NHEK) cultures in accordance with the use of jet fuel showed similarities between porcine 
keratinocytes and NHEK in terms of TNF- and IL-8 expression [71]. Another experiment that 
demonstrated the chemical irritants induced the production of IL-1, TNF- and IL-8 [72]. These 
findings indicate that the secretion of pro-inflammatory and chemotactic cytokines may provide a 
useful biomarker for determining the toxicity level of irritants on human skin. 
One study has suggested that environmental pollutants such as diesel exhaust particles and 
formaldehyde affect the ability of human skin keratinocytes to release pro-inflammatory cytokines (IL-
1, IL-8 and TNF-) [73]. It has been reported that IL-8 production by keratinocytes is under the 
control of protein kinase C [74] and that protein kinase C signaling pathways are altered in 
keratinocytes from patients with psoriasis [75]. Therefore, by quantitatively examining the amount 
(pg/ml) of human IL-1, IL-8 and TNF- secreted from treated pNHEK cultures, using the enzyme-
linked immunosorbent assay (ELISA), the in vitro biocompatibility of chitosan derivatives can be 
evaluated in more detail.  
 
5. Future Considerations and Conclusions 
 
Chitosan and its various derivatives have a wide range of applications. They may be employed to 
solve numerous problems in environmental and biomedical engineering. For example, hydroxymethyl 
chitin and water-soluble chitosan derivatives are useful for anionic waste streams. While chitosan N-
benzylsulfonate derivatives can be used as sorbents for removal of metal ions in an acidic medium. 
Deacetylated chitosan can be easily molded into various forms and their derivatives are digested in 
vivo by lysozomal enzymes. Therefore, it appears that chitosan derivatives can be used as a carrier of a Int. J. Mol. Sci. 2009, 10                 
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variety of drugs for controlled release applications. Chitosan is useful to be a bio-scaffold for tissue 
engineering especially for skin and bone. Chitosan in the form of porous structure can serve as a 
template for bone osteoblasts or skin fibroblasts and keratinocytes where the cells can grow within the 
scaffold and form accordingly to the shape of the scaffold. For example, chitosan porous structure in a 
thin-sheet alike can represent a scaffold for skin where skin fibroblasts and keratinocytes grow to form 
a basic skin substitutes in vitro. Furthermore, chitosan possesses all the characteristics required for an 
ideal contact lens such as optical clarity, mechanical stability, sufficient optical correction, gas 
permeability, wettability and immunological compatibility. Recently, the transdermal absorption 
promoting characteristics of chitosan have been explored for nasal and oral delivery of polar drugs to 
include peptides and proteins and for vaccine delivery. These properties have enabled the chitosan 
together with appropriate derivatives to be a promising biomaterial for pharmaceutical industry and the 
other applications. 
For the establishing of in vitro biocompatibility models, the comparison with experimental animals 
using in vivo toxicity studies is also very useful. However, it is unlikely that the toxicity studies in 
experimental animals can be completely replaced, since biocompatibility of biomedical-grade chitosan 
is a complex phenomenon encompassing amongst other immune reactions and interactions with 
various inflammatory cells. Furthermore, interpretative problems occur because tissue reactions to 
newly synthesized biomedical-grade chitosan is very complicated that leads to the difficulty to 
separate between the cytotoxicity and differentiation of replacement skin tissues from inflammatory 
and immune reactions of the surrounding connective tissue in vivo. However, by correlating the 
biocompatibility results both from in vitro and in vivo, we can be more assured with the safety use of 
newly synthesized biomedical-grade chitosan on the human, although the exact results would be after 
clinical application on human. Biocompatibility in vitro is useful to characterize cytotoxic effects of 
leachable materials, such as residual monomers, catalysts as well as polymer erosion and related 
factors (e.g. composition, molecular weight and polydispersity) which are suitable to monitor the 
quality and purity of the biodegradable biomedical-grade chitosan. Besides, in vitro model also enables 
the study of single cell proliferation and invasion pattern within a porous structured biomedical-grade 
chitosan in which in vivo model may be less efficient in the situation. Moreover, by analyzing the cells 
invasion pattern within a bio-scaffold or porous biomedical-grade chitosan, not only can produce 
cytotoxicity evaluation but in the meanwhile the structure of the scaffold can be well defined and 
engineered. Advances in technology and the understanding of biology, chemistry and related fields 
will inevitably lead to advances of the present in vitro biocompatibility models as well as to new 
models. Recently, improvement in the in vitro biocompatibility has been on the use of coculture model 
especially skin tissues. This model mainly serves to evaluate a more complicated molecular responses 
and cascades provoked by test substances. Additionally, the application of human-skin like tissue 
model such as Epiderm
™ skin model has also been implemented to further resemble human in vivo 
situation for the studies such as in vitro skin irritation, dermal corrosion, dermal phototoxicity, 
percutaneous absorption, transdermal drug delivery skin inflammation and skin psoriasis research. 
However, it is not cost-effective if only cytotoxicity to be performed.  
In the biocompatibility assessment of any newly developed biomaterial, in vitro tests should be 
conducted prior to in vivo tests in order to minimize the risk to humans and animals. The study of 
biocompatibility  in vitro enables the detailed evaluation of not only cellular, but also molecular Int. J. Mol. Sci. 2009, 10                 
 
1309
responses. Biomedical-grade chitosan can be enriched with various derivatives to achieve the desired 
or proposed functionality. However, derivatives enrichment may trigger different responses at cellular 
and molecular level. There could be insufficient proof to ensure the complete biocompatibility in vitro 
if one performs only cell viability because biomedical-grade chitosan derivatives may provoke 
genotoxic responses which will eventually lead to cell death. Thus, in vitro biocompatibility 
assessment for wound management must consider cytocompatibility, genotoxicity and related pro-
inflammatory cytokines expression for better in vitro biocompatibility evaluation. 
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